Injectable pH-responsive Ureido-Pyrimidinone (UPy) hydrogel as drug carrier for epicardial activation
F.C. Lauta (TU Delft - Mechanical Engineering)
E.L. Fratila-Apachitei – Mentor (TU Delft - Biomaterials & Tissue Biomechanics)
Amir Zadpoor – Graduation committee member (TU Delft - Biomaterials & Tissue Biomechanics)
M-J TH Goumans – Graduation committee member (Leiden University Medical Center)
Esther Dronkers – Graduation committee member (Leiden University Medical Center)
Elizabeth Carroll – Graduation committee member (TU Delft - ImPhys/Charged Particle Optics)
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
The presence of a stem cell source in the epicardium that can be stimulated by exogenous delivery of transforming growth factor-β (TGF-β) and migrate towards the myocardium can represent a new approach to achieve cardiac repair following myocardial infarction. However, injection of drugs always requires use of carriers which help stabilize the compound in the harsh and dynamic environment of the heart. To this extent, pH-responsive drug delivery systems represent an enthralling approach to ensure minimal invasiveness, instantaneous responsiveness, and targeted delivery of the incorporated compound. In this in vitro study we aimed to validate an Ureidopyrimidinone-based supramolecular hydrogel as TGF-β carrier for epicardial activation. The results demonstrated the capacity of the hydrogel to respond to pH changes and deliver the growth factor, which retained its ability to activate its signalling pathway and stimulate treated cells.